Capillon Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 12-12-2024
- Paid Up Capital ₹ 0.30 M
as on 12-12-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 12-12-2024
- Revenue 50.59%
(FY 2021)
- Profit 2.71%
(FY 2021)
- Ebitda -5.97%
(FY 2021)
- Net Worth -2863.53%
(FY 2021)
- Total Assets -15.13%
(FY 2021)
About Capillon Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹1.00 M.
Kapil Kumar and Pushpa Devi serve as directors at the Company.
- CIN/LLPIN
U24232HP2014PTC000790
- Company No.
000790
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Oct 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Capillon Pharma Private Limited offer?
Capillon Pharma Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Common Disease Medicines, Antihistamines, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Ayurvedic & Herbal Health Supplement, Herbal Sexual Health Supplement, Nutraceuticals & Dietary Supplements, Dietary Supplements.
Who are the key members and board of directors at Capillon Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kapil Kumar  | Director | 16-Oct-2014 | Current |
| Pushpa Devi | Director | 16-Oct-2014 | Current |
Financial Performance of Capillon Pharma.
Capillon Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 50.59% increase. The company also saw a slight improvement in profitability, with a 2.71% increase in profit. The company's net worth observed a substantial decline by a decrease of 2863.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Capillon Pharma?
In 2021, Capillon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Nov 2017 | ₹1.00 M | Open |
How Many Employees Work at Capillon Pharma?
Unlock and access historical data on people associated with Capillon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Capillon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Capillon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
